Cullinan Therapeutics, Inc.
CGEM
$9.07
$0.111.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.00% | 9.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.09% | 12.68% | |||
| Operating Income | 0.09% | -12.68% | |||
| Income Before Tax | -2.04% | -17.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.79% | -17.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.79% | -17.47% | |||
| EBIT | 0.09% | -12.68% | |||
| EBITDA | 0.09% | -12.69% | |||
| EPS Basic | -1.23% | -16.99% | |||
| Normalized Basic EPS | -1.48% | -16.71% | |||
| EPS Diluted | -1.23% | -16.99% | |||
| Normalized Diluted EPS | -1.48% | -16.71% | |||
| Average Basic Shares Outstanding | 0.55% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.55% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||